The development of orally administrable gemcitabine prodrugs with d-enantiomer amino acids: Enhanced membrane permeability and enzymatic stability

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 86, Issue 3, 2014, Pages 514-523

  Tsume, Yasuhiro ^a   Incecayir, Tuba ^b   Song, Xueqin ^c   Hilfinger, John M ^d   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b GAZI UNIVERSITY   (Turkey)

^c Hospira Inc   (United States)

^d TSRL INC   (United States)

Author keywords

Amino acid; Monoester gemcitabine prodrugs; Mouse in situ perfusion; Permeability; Stability; Unnatural form

Indexed keywords

DEXTRO AMINO ACID; GEMCITABINE; GEMCITABINE PRODRUG; PRODRUG; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; AMINO ACID; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG HYDROLYSIS; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVATION; FEMALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CACO 2 CELL LINE; CHEMISTRY; DRUG EFFECTS; ENZYME STABILITY; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; STEREOISOMERISM;

ADMINISTRATION, ORAL; AMINO ACIDS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DEOXYCYTIDINE; ENZYME STABILITY; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PRODRUGS; STEREOISOMERISM;

EID: 84898429563     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.12.009     Document Type: Article

References (54)

1. C.J. van Moorsel, G.J. Peters, and H.M. Pinedo Gemcitabine: future prospects of single-agent and combination studies Oncologist 2 1997 127 134
2. Y. Zhang, W.Y. Kim, and L. Huang Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy Biomaterials 34 2013 3447 3458
3. H. Han, R.L. de Vrueh, J.K. Rhie, K.M. Covitz, P.L. Smith, C.P. Lee, D.M. Oh, W. Sadee, and G.L. Amidon 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter Pharm. Res. 15 1998 1154 1159
4. H.K. Han, D.M. Oh, and G.L. Amidon Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter Pharm. Res. 15 1998 1382 1386
5. X. Song, P.L. Lorenzi, C.P. Landowski, B.S. Vig, J.M. Hilfinger, and G.L. Amidon Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport Mol. Pharm. 2 2005 157 167
6. X. Song, B.S. Vig, P.L. Lorenzi, J.C. Drach, L.B. Townsend, and G.L. Amidon Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1- (beta-d-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter J. Med. Chem. 48 2005 1274 1277
7. R.S. Talluri, S.K. Samanta, R. Gaudana, and A.K. Mitra Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir Int. J. Pharm. 361 2008 118 124
8. S. Tolle-Sander, K.A. Lentz, D.Y. Maeda, A. Coop, and J.E. Polli Increased acyclovir oral bioavailability via a bile acid conjugate Mol. Pharm. 1 2004 40 48
9. Y. Tsume, J.M. Hilfinger, and G.L. Amidon Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability Mol. Pharm. 5 2008 717 727
10. Y. Tsume, B.S. Vig, J. Sun, C.P. Landowski, J.M. Hilfinger, C. Ramachandran, and G.L. Amidon Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters Molecules 13 2008 1441 1454
11. B.S. Vig, P.J. Lorenzi, S. Mittal, C.P. Landowski, H.C. Shin, H.I. Mosberg, J.M. Hilfinger, and G.L. Amidon Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis Pharm. Res. 20 2003 1381 1388
12. T. Kawaguchi, M. Saito, Y. Suzuki, N. Nambu, and T. Nagai Specificity of esterases and structure of prodrug esters. II. Hydrolytic regeneration behavior of 5-fluoro-2′-deoxyuridine (FUdR) from 3′,5′-diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity Chem. Pharm. Bull. (Tokyo) 33 1985 1652 1659
13. C.P. Landowski, X. Song, P.L. Lorenzi, J.M. Hilfinger, and G.L. Amidon Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism Pharm. Res. 22 2005 1510 1518
14. C.P. Landowski, B.S. Vig, X. Song, and G.L. Amidon Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs Mol. Cancer Ther. 4 2005 659 667
15. Y. Nishizawa, and J.E. Casida 3′,5′-Diesters of 5-fluoro-2′-deoxyuridine: synthesis and biological activity Biochem. Pharmacol. 14 1965 1605 1619
16. B.S. Anand, J. Patel, and A.K. Mitra Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2 J. Pharmacol. Exp. Therap. 304 2003 781 791
17. G.M. Friedrichsen, W. Chen, M. Begtrup, C.P. Lee, P.L. Smith, and R.T. Borchardt Synthesis of analogs of l-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells Eur. J. Pharm. Sci. 16 2002 1 13
18. A. Guo, P. Hu, P.V. Balimane, F.H. Leibach, and P.J. Sinko Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line J. Pharmacol. Exp. Therap. 289 1999 448 454
19. T. Hatanaka, M. Haramura, Y.J. Fei, S. Miyauchi, C.C. Bridges, P.S. Ganapathy, S.B. Smith, V. Ganapathy, and M.E. Ganapathy Transport of amino acid-based prodrugs by the Na+- and Cl(-)-coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery J. Pharmacol. Exp. Therap. 308 2004 1138 1147
20. D.D. Phan, P. Chin-Hong, E.T. Lin, P. Anderle, W. Sadee, and B.J. Guglielmo Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor Antimicrob. Agents Chemother. 47 2003 2351 2353
21. N.S. Umapathy, V. Ganapathy, and M.E. Ganapathy Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+) Pharm. Res. 21 2004 1303 1310
22. B.S. Anand, S. Katragadda, and A.K. Mitra Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism J. Pharmacol. Exp. Therap. 311 2004 659 667
23. D. Meredith, C.S. Temple, N. Guha, C.J. Sword, C.A. Boyd, I.D. Collier, K.M. Morgan, and P.D. Bailey Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1 Eur. J. Biochem. 267 2000 3723 3728
24. C.U. Nielsen, R. Andersen, B. Brodin, S. Frokjaer, M.E. Taub, and B. Steffansen Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line J. Control. Release 76 2001 129 138
25. M. Satake, M. Enjoh, Y. Nakamura, T. Takano, Y. Kawamura, S. Arai, and M. Shimizu Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers Biosci. Biotechnol. Biochem. 66 2002 378 384
26. N. Surendran, K.M. Covitz, H. Han, W. Sadee, D.M. Oh, G.L. Amidon, R.M. Williamson, C.F. Bigge, and B.H. Stewart Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDA antagonist Pharm. Res. 16 1999 391 395
27. U. Wenzel, I. Gebert, H. Weintraut, W.M. Weber, W. Clauss, and H. Daniel Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells J. Pharmacol. Exp. Therap. 277 1996 831 839
28. U. Wenzel, D.T. Thwaites, and H. Daniel Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter Br. J. Pharmacol. 116 1995 3021 3027
29. I. Rubio-Aliaga, and H. Daniel Mammalian peptide transporters as targets for drug delivery Trends Pharmacol. Sci. 23 2002 434 440
30. Y. Tsume, J.M. Hilfinger, and G.L. Amidon Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study Pharm. Res. 28 2011 2575 2588
31. D.E. Gonzalez, K.M. Covitz, W. Sadee, and R.J. Mrsny An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2 Cancer Res. 58 1998 519 525
32. J. Garcia-Manteiga, M. Molina-Arcas, F.J. Casado, A. Mazo, and M. Pastor-Anglada Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 9 2003 5000 5008
33. J.L. Grem 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development Invest. New Drugs 18 2000 299 313
34. O. Kahramanogullari, G. Fantaccini, P. Lecca, D. Morpurgo, and C. Priami Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy PLoS ONE 7 2012 e50176
35. S.A. Veltkamp, D. Pluim, M.A. van Eijndhoven, M.J. Bolijn, F.H. Ong, R. Govindarajan, J.D. Unadkat, J.H. Beijnen, and J.H. Schellens New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′- difluorodeoxyuridine Mol. Cancer Ther. 7 2008 2415 2425
36. V.J. O'Neill, and C.J. Twelves Oral cancer treatment: developments in chemotherapy and beyond Br. J. Cancer 87 2002 933 937
37. F.E. Stuurman, B. Nuijen, J.H. Beijnen, and J.H. Schellens Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement Clin. Pharmacokinet. 52 2013 399 414
38. G.D. Birnie, H. Kroeger, and C. Heidelberger Studies of fluorinated pyrimidines. Xviii. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase Biochemistry 2 1963 566 572
39. J. Bonastre, P. Jan, Y. Barthe, and S. Koscielny Metastatic breast cancer: we do need primary cost data Breast 21 2012 384 388
40. T. Incecayir, Y. Tsume, and G.L. Amidon Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification Mol. Pharm. 2013
41. Y. Tsume, C.J. Provoda, and G.L. Amidon The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, alpha-fluoro-beta-ureidopropionate, alpha-fluoro-beta-alanine using LC-MS J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 879 2011 915 920
42. B.S. Anand, S. Dey, and A.K. Mitra Current prodrug strategies via membrane transporters/receptors Expert Opin. Biol. Ther. 2 2002 607 620
43. M.E. Ganapathy, W. Huang, H. Wang, V. Ganapathy, and F.H. Leibach Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2 Biochem. Biophys. Res. Commun. 246 1998 470 475
44. H. Steingrimsdottir, A. Gruber, C. Palm, G. Grimfors, M. Kalin, and S. Eksborg Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy Antimicrob. Agents Chemother. 44 2000 207 209
45. S. Weller, M.R. Blum, M. Doucette, T. Burnette, D.M. Cederberg, P. de Miranda, and M.L. Smiley Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers Clin. Pharmacol. Ther. 54 1993 595 605
46. A.H. Eriksson, P.L. Elm, M. Begtrup, R. Nielsen, B. Steffansen, and B. Brodin HPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives Mol. Pharm. 2 2005 242 249
47. J. Li, K. Tamura, C.P. Lee, P.L. Smith, R.T. Borchardt, and I.J. Hidalgo Structure-affinity relationships of Val-Val and Val-Val-Val stereoisomers with the apical oligopeptide transporter in human intestinal Caco-2 cells J. Drug Target. 5 1998 317 327
48. K. Tamura, P.K. Bhatnagar, J.S. Takata, C.P. Lee, P.L. Smith, and R.T. Borchardt Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2 Pharm. Res. 13 1996 1213 1218
49. J. Vabeno, T. Lejon, C.U. Nielsen, B. Steffansen, W. Chen, H. Ouyang, R.T. Borchardt, and K. Luthman Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations J. Med. Chem. 47 2004 1060 1069
50. P.L. Lorenzi, C.P. Landowski, X. Song, K.Z. Borysko, J.M. Breitenbach, J.S. Kim, J.M. Hilfinger, L.B. Townsend, J.C. Drach, and G.L. Amidon Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo J. Pharmacol. Exp. Therap. 314 2005 883 890
51. F. Cao, Y. Gao, and Q. Ping Advances in research of PepT1-targeted prodrug Asian J. Pharm. Sci. 7 2012 110 122
52. Y. Tsume, and G.L. Amidon The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme Molecules 17 2012 3672 3689
53. P.W. Woodman, A.M. Sarrif, and C. Heidelberger Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′- deoxyuridine Cancer Res. 40 1980 507 511
54. C.P. Landowski, P.L. Lorenzi, X. Song, and G.L. Amidon Nucleoside ester prodrug substrate specificity of liver carboxylesterase J. Pharmacol. Exp. Therap. 316 2006 572 580